Post hoc analysis of the CANTREAT randomised trial
1 December 2023
| Sofia Rokerya
|
Retina / Uvea / Vitreous
|
Age-related macular degeneration, Randomized clinical trial, Ranibizumab, Treat-and-extend
CANTREAT, a Canadian multicentre two-year randomised trial compares treat and extend treatment (T&E) relative to the monthly administration of Ranibizumab in nAMD. Two-hundred and eighty-five treatment-naïve patients with nAMD were randomised to receive either a once-monthly dosing or T&E regimen...
